Navigation Links
Haemacure Reports Third Quarter 2007 Results
Date:8/31/2007

>Complete financial statements for the quarter ended July 31, 2007 are available on Haemacure's web site, http://www.haemacure.com, and have been filed on Sedar.

Financial Highlights

(unaudited)

Quarters ended

July 31, July 31,

2007 2006

------------ ------------

Sales $ 31,674 $ 31,409

Gross profit $ 12,943 $ 17,042

Gross margin 41% 54%

Selling and marketing expenses - $ 13,105

General and administrative expenses $ 734,286 $ 522,444

Total expenses $ 869,822 $ 741,205

Net loss $ (856,879) $ (724,163)

Loss per share $ (0.01) $ (0.02)

Weighted average number of shares

outstanding 163,800,917 38,800,917

As at As at

July 31, October 31,

2007 2006

------------ ------------

Cash and cash equivalents $ 4,292,487 $ 78,300

Temporary investment $ 4,007,200 $ 441,000

Total assets $11,726,205 $ 2,696,198

Shareholders' equity $10,138,094 $ 981,381


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 1Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 2Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 4Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 5AMT Appoints New Chief Executive Officer 58224 1AMT Appoints New Chief Executive Officer 58224 2AMT Appoints New Chief Executive Officer 58224 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 1ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 2ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 4